# Reversible Biological Acetylation in Health and Disease

> **NIH NIH R13** · FEDERATION OF AMER SOC FOR EXPER BIOLOGY · 2024 · $15,000

## Abstract

Program Summary
We seek funding for the conference "Reversible Biological Acetylation in Health and Diseases" under the
auspices of the Federation of American Societies for Experimental Biology (FASEB). The 2024 conference
will be the 9th meeting of this highly valued biennial conference. This unique forum attracts scientists with
diverse expertise in biochemistry, structural biology, cell and molecular biology, developmental biology,
translational and clinical research. We aim to showcase the latest conceptual insights and technical
advances in the field. This meeting is particularly timely because of exciting new fundamental discoveries in
the linkage of acetylation, metabolism, 3D chromatin and cancer. Furthermore, novel small molecular
inhibitors are being developed to effectively block oncogenic lysine acetyltransferases or lysine
deacetylases. A provisional cutting-edge program provides a balanced survey of groundbreaking basic
and translational research. Major topics include: 1) Writers of protein acetylation; 2) Readers of protein
acetylation; 3) Erasers of protein acetylation; 4) 3D chromatin organization; 5) Metabolic regulation of
reversible acetylation; 6) Biological acetylation in cancer; 7) Biological acetylation in development and
aging; 8) ‘Omics’ in acetylation; and 9) Chemical biology and drug development.
The FASEB meeting traditionally brings all participants in a single conference venue for unopposed sessions.
The format includes plenary and poster sessions, with the former covering state-of-the-art topics by leaders
in the field and cutting-edge and timely oral presentations selected from submitted poster abstracts from
junior colleagues, particularly pre- and post-doctoral trainees. This ensures active engagement of junior
participants in the conference and stimulates attendance at poster sessions. Moreover, there will be a ‘meet
the speaker’ period following each plenary session. Two interactive workshops are planned, one on diversity
networking, and another on career development for early investigators. Both workshops offer participants the
opportunity to informally share challenges and solutions that they encounter at the workplace and to promote
awareness of the diversity of peoples’ situations, allyship, networking and mentorship.
The primary objective of the conference is to bring together top basic scientists, and clinician investigators to
foster interdisciplinary collaborations. A second objective is to help development of a new generation of
scientists investigating molecular mechanisms involving KATs and KDACs. The organizers will make a
concerted effort to design a meeting that engages and serves our pre- and postdoctoral trainees, early-stage
independent investigators and scientists from under-represented groups. We provide travel awards and best-
poster awards as well as plenary talk opportunities for accomplished early investigators and investigators
from under-represented communities to enhance their interna...

## Key facts

- **NIH application ID:** 10897361
- **Project number:** 1R13CA290701-01
- **Recipient organization:** FEDERATION OF AMER SOC FOR EXPER BIOLOGY
- **Principal Investigator:** Yali Dou
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $15,000
- **Award type:** 1
- **Project period:** 2024-08-01 → 2025-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10897361

## Citation

> US National Institutes of Health, RePORTER application 10897361, Reversible Biological Acetylation in Health and Disease (1R13CA290701-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10897361. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*